The challenges of distributing COVID-19 vaccinations

Abstract

Pfizer/BioNTech reported the preliminary efficacy results for their COVID-19 vaccine, confirming levels of 95% on November 18. On November 16, Moderna announced 95% efficacy and 2 days later, the Oxford and AstraZeneca group reported safety and immunogenicity across a wider range of groups As attention turns to deployment, we need transparency about vaccine distribution and implementation. Success will hinge on collaboration of complex networks of government, companies, health workers and the public.

Topics & Concepts